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 ข่าเล็กถูกน ามาใช้เป็นยาแผนโบราณเพื่อรักษาโรคต่างๆ ในทวีปเอเชียมาเป็นเวลานาน  
สารสกดัจากข่าเล็กถูกพบวา่มีฤทธ์ิตา้นเช้ือแบคทีเรีย แต่ยงัไม่เคยมีรายงานถึงฤทธ์ิในการตา้นเช้ือรา 
การศึกษาน้ีจึงมีวตัถุประสงคเ์พื่อทดสอบฤทธ์ิตา้นเช้ือรา Candida albicans ของสารสกดัจากเหงา้
ของข่าเล็ก เคยมีรายงานวา่ galangin เป็นสารประกอบหลกักลุ่มฟลาโวนอยดท่ี์พบในข่าเล็ก จากการ
วเิคราะห์ดว้ยโครมาโทกราฟีสมรรถนะสูงในการศึกษาน้ีพบวา่ สารสกดัข่าเล็กท่ีใช ้80% อะซิโตน
สกดัมีปริมาณ galangin อยู ่ 3.38 มิลลิกรัมต่อกรัม และจากการตรวจสอบดว้ยวิธี disc diffusion 
พบวา่สารสกดัข่าเล็กมีฤทธ์ิตา้นเช้ือรา C. albicans  ถึงแมว้า่ galangin จะสามารถยบัย ั้งการเจริญ
ของเช้ือราชนิดน้ีได ้แต่จากการท า bioautography ท  าให้ทราบวา่ galangin ไม่ใช่สารออกฤทธ์ิหลกั
ในการตา้นเช้ือราชนิดน้ี เน่ืองจากปริมาณของ galangin ท่ีมีอยู่ในสารสกดัต ่ามาก ความเขม้ขน้
ต ่าสุดของสารสกดัข่าเล็กท่ีสามารถยบัย ั้งการเจริญของเช้ือรา C. albicans (MIC) และความเขม้ขน้
ต ่าสุดท่ีสามารถฆ่าเช้ือรา C. albicans (MFC) ได ้คือ 1.2 และ 2.0 มิลลิกรัมต่อมิลลิลิตร ตามล าดบั 
เม่ือสังเกตดว้ยกลอ้งจุลทรรศน์แบบเฟสคอนทรัสต์และวดัการสร้างไบโอฟิล์มดว้ยวิธี สเปกโทรส
โกปี พบว่าสารสกดัสามารถยบัย ั้งการสร้างไบโอฟิล์มของเช้ือรา C. albicans ได ้ ผูว้ิจยัไดท้  าการ
ประเมินผลการท าลายเซลล์ของเช้ือราผ่านกลอ้งจุลทรรศน์อิเล็กตรอนแบบส่องกราด (SEM) เพื่อ
คน้หากลไกการออกฤทธ์ิในการตา้นเช้ือรา C. albicans พบวา่ สารสกดัท าให้เกิดการเปล่ียนแปลง
รูปร่างของเซลล ์โดยพบผวิเซลล์เกิดความขรุขระมากข้ึนเม่ือมีการเติมสารสกดัความเขม้ขน้ท่ี MIC 
และเม่ือเล้ียงเช้ือราด้วยด้วยอาหารเล้ียงเช้ือท่ีมีสารสกัดข่าเล็กความเข้มข้นท่ี MFC เซลล์จะ
เปล่ียนแปลงรูปร่างจากวงรีไปสู่รูปร่างท่ีกลมมากกวา่เดิม จากผลการทดลองน้ีช้ีแนะถึงความเป็นไป
ได้ท่ีสารสกดัข่าเล็กมีฤทธ์ิตา้นเช้ือราโดยการไปท าลายผนังเซลล์ ส่งผลท าให้เซลล์เปล่ียนเป็น  
สเฟียโรพลาส และตายในท่ีสุด อยา่งไรก็ตามกลไกการออกฤทธ์ิท่ีน าเสนอน้ียงัมีความจ าเป็นตอ้ง
ศึกษาทดลองต่อไปเพื่อยนืยนัวา่เกิดการท าลายผนงัเซลล์จริง นอกจากนั้นสารออกฤทธ์ิท่ีรับผิดชอบ
ต่อฤทธ์ิตา้นเช้ือราของสารสกดัก็ยงัจ  าเป็นตอ้งมีการศึกษาเพิ่มเติมต่อไป 
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 Alpinia officinarum Hance has long been used as traditional medicine for many 
ailments in Asia. The extract of A. officinarum has been shown to possess 
antibacterial activity. However, antifungal activity of this plant has not been reported. 
The purpose of this study was to determine an antifungal potential of A. officinarum 
on Candida albicans. Galangin was reported to be a major flavonoid compound in the 
rhizomes of A. officinarum. In the present study, a content of galangin in 80% acetone 
extract of A. officinarum was 3.38 mg/g, analyzed by a high performance liquid 
chromatography (HPLC). By a disc diffusion method, it was found that the A. 
officinarum extract possessed antifungal activity against C. albicans. Although 
galangin inhibited growth of this fungus, the results from bioautography revealed that 
galangin was not responsible for this activity of A. officinarum rhizomes extract due 
to its very low amount in the extract. The minimum inhibitory concentration (MIC) 
and minimum fungicidal concentration (MFC) of the extract were 1.2 and 2.0 mgml, 
respectively. An inhibitory effect of the extract on Candida biofilm formation was 
revealed by using phase contrast microscopy and spectrometry. The assessment of cell 
damage was conducted through scanning electron microscope (SEM) observation to 
find the mechanism underlying this antimicrobial activity. SEM analysis showed that 
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the extract induced deformation of C. albicans. The cells treated with MIC of the 
extract had coarse surface and changed from oval to rounder shape when treated with 
MFC. These results suggested that the extract possess’d antifungal activity possibly 
by damaging cell wall, causing C. albicans to form spheroplast, and finally death. 
However, this postulated mechanism, which contributes to an explanation for its 
antifungal activity against C. albicans, needs more experiments to confirm the actual 
disruption of yeast cell wall. Moreover, the isolation and identification of the active 
ingredient(s) responsible for this action need further investigation. 
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 CHAPTER I 
INTRODUCTION 
 
1.1 Background/Problem 
 Candida albicans resides in a diversity of organ surfaces of a healthy host, such 
as oral cavity, digestive tract, skin and vagina. As an opportunistic pathogen, it can 
cause life-threatening systemic infection in patients who are severely 
immunocompromised due to cancer chemotherapy, organ or bone marrow 
transplantation and human immunodeﬁciency virus (HIV) infection, especially in 
HIV-infected patients (Calderone and Fronzi, 2001). C. albicans is an organism that is 
most often associated with serious fungal diseases among those in immune-
compromised patients (Fridkin and Jarvis, 1996). Moreover, candidal vaginitis is 
predominantly caused by strains of C. albicans (Sobel et al., 2001), and appears to be 
a common problem both in immunocompetent and healthy women. Despite advances 
in antifungal therapies, the number of problems remains to be solved for most 
antifungal drugs available, including resistance (Sojakova, Liptajova, Borovsky, and 
Subik, 2004) and toxicity (Laniado-Laborin and Cabrales-Vargas, 2009). These 
problems lead to the need of novel, safe, and effective antifungal compounds. 
 Biofilms are aggregates of unicellular micro-organisms forming multicellular 
structures that adhere to surfaces. Their formation occurs in response to a variety of 
cues, including high cell density, nutrient deprivation and physical environmental 
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stresses. Pathogenic bacteria and fungi can form biofilms on inert surfaces of 
implanted devices such as catheters, prosthetic heart valves and joint replacements. 
Because biofilms are generally more resistant to both host defence mechanisms and to 
antibiotics than planktonic unicellular microbes, they represent an ongoing source of 
infection for many patients (Li, Yan, and Xu, 2003), and therefore are increasingly 
recognized as important health problems for patients with microbial infections. 
Although the majority of these infections are caused by bacteria, fungal infections are 
becoming increasingly common, especially those caused by species in the genus 
Candida, including C. albicans. Since C. albicans forms biofilm on mucosal surfaces 
and on plastic surfaces of indwelling devices (Hasan, Xess, Wang, Jain, and Fries, 
2009), it has been proposed that this fungus develops phenotypic adaptation within 
the bioﬁlm matrix, resulting in drug-resistance. 
 Plants (fruits, vegetables, medicinal herbs, etc.) provide abundant resources of 
antimicrobial compounds, such as phenolic compounds, nitrogen containing 
compounds, vitamins, terpenoids and some other secondary metabolites. They are rich 
in valuable bioactivities, e.g., antioxidant, anti-inflammatory, antitumor, anti-
mutagenic, anti-carcinogenic, antiviral and antibacterial activities. Flavonoids, a 
group of phenolic compounds in plants, have shown significant antimicrobial  
activities (Cushnie and Lamb, 2005). 
 Alpinia officinarum Hance (Zingiberaceae) known as lesser galangal, a pungent 
and aromatic plant, is used as spice ingredient for flavoring food throughout 
southeastern Asian countries (Ly, Shimoyamada, Kato, and Yamauchi, 2003). It has 
also been used in a traditional medicine for several purposes, such as relieving 
stomachache and pain, treating colds, invigorating the circulatory system, reducing 
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swelling and inflammation (An et al., 2008; Lee et al., 2009; Matsuda, Ando, Kato, 
Morikawa, and Yoshikawa, 2006). The crude extract of the rhizomes of A. 
officinarum as well as its bioactive components has been shown to possess 
antibacterial activity (Zhang, Dai, Liao, and Ding, 2010). However, antifungal activity 
of this plant has not been reported. 
 Several chemical compositions in the rhizomes of A. officinarum have been 
isolated and identified. They include monoterpenes, neolignans, diarylheptanoids, 
phenylpropanoids, and flavonoids (An, Zhang, Xu, Yang, and Zou, 2009; An et al. 
2008; Ly, Yamauchi, and Kato, 2001; Shin, Kinoshita, Koyama, and Takahashi, 2002; 
Zhao, Qu, Fu, and Liang, 2010). The flavonol galangin (3,5,7-trihydroxyflavone) is a 
major constituent of A. officinarum (Cushnie and Lamb, 2006). Galangin possesses 
certain biological activities, such as anti-genotoxicity (Heo, Sohn, and Au, 2001) and 
antibacterial activity (Cushnie and Lamb, 2006). It is possible that the extract from 
rhizomes of A. offcinarum may have potential to possess antifungal activity against 
this type of fungus. 
 The aims of this study were to determine the inhibitory effect of the crude 
extracts from rhizomes of A. officinarum and its major flavonoid, galangin, against C. 
albicans. The crude extract of Cassia spectabilis has been reported to inhibit the 
biofilm formation and alter morphology of C. albican (Sangetha, Zuraini, Suryani, 
and Sasidharan, 2009). In the present study, cellular surface changes of C. albicans 
were examined by scanning electron microscope as well. 
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1.2 Research Objectives 
 1.2.1 To determine the inhibitory effect of galangin and the crude extract of 
rhizomes of A. officinarum against C. albicans. 
 1.2.2 To isolate and quantitate galangin from the crude extract of rhizomes of 
A. officinarum. 
 1.2.3 To determine whether crude extract from the rhizomes of A. officinarum 
changes cellular surface of C. albicans. 
 1.2.4 To determine whether the crude extract of rhizomes of A. officinarum 
prevents biofilm formation of C. albicans. 
 
1.3 Research hypotheses 
 1.3.1 The crude extract of rhizomes of A. officinarum possesses anticandidal 
activity with galangin as bioactive substance. 
 1.3.2 The crude extract from rhizomes changes cellular surface of C. albicans 
and prevents biofilm formation of C. albicans. 
 
1.4 Scope and limitations of the study 
 The obtained data is limited to in vitro study. Clinical trial is needed to confirm 
the beneficial use of the extract. 
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CHAPTER II 
LITERATURE REVIEW 
 
2.1 Candida albicans 
 The genus Candida belongs to yeasts. It is also the most common cause of 
opportunistic mycoses worldwide. It is a frequent colonizer of human skin and 
mucous membranes. Candida is a member of normal flora of skin, mouth, vagina, and 
bowel. In addition to being a colonizer and pathogen, it is found in the environment, 
particularly on leaves, flowers, water and soil. However, if the immune defenses of 
the host become compromised, they can cause severe systemic infections. These 
include especially the patients in risk factors include infection by the human 
immunodeficiency virus (HIV), anti-cancer therapy, organ transplantation, abdominal 
surgery, catheters, diabetes and the use of broad-spectrum antibiotics (Cruz et al., 
2002; Morschhauser, 2002). The genus Candida includes around 154 species. Among 
these, six are most frequently isolated in human infections. While Candida albicans is 
the most abundant and significant species, Candida tropicalis, Candida glabrata, 
Candida parapsilosis, Candida krusei and Candida lusitaniae are also isolated as 
causative agents of Candida infections (Abi-Said et al., 1997). The most important of 
Candida spp. is C. albicans which is the most frequently isolated. It is also believed to 
be the most virulent in human (McCullough, Ross, and Reade, 1996). 
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 2.1.1 Taxonomy of C. albicans 
  C. albicans belongs to the Ascomycota class of fungi and is the most 
commonly studied species because it causes a variety of mycotic infections in humans 
(Siqueira and Sen, 2004) 
Taxonomy 
 Kingdom: Fungi 
 Phylum: Ascomycota 
 Subphylum: Ascomycotina 
 Class: Ascomycetes 
 Order: Saccharomycetales 
 Family: saccharomycetaceae 
 Genus: Candida 
 Species: albicans 
 2.1.2 Structure of C. albicans 
  The cell wall of C. albicans is consisted of the polysaccharides mannan, 
glucan, and chitin (Calderone and Braun, 1991). The percent compositions of cell 
walls from yeast cells and germ tubes are relatively similar, although the amounts of 
glucans and chitin from C. albicans vary according to the growth form (Chattaway, 
Holmes, and Barlow, 1968). The relationships of these polymers to each other are 
presented in Figure 2.1. 
 2.1.3 Morphology of C. albicans 
  The fungal pathogen C. albicans can be found in three morphological 
states, which are shown in Figure 2.2 as yeasts, pseudohyphae and hyphae (Sudbery, 
Gow, and Berman, 2004).  
 
 
 
 
 
 
 
 
 7 
 
Figure 2.1 Schematic diagram of the cell wall of C. albicans. The layers are enriched 
in the indicated components. However, mannoprotein is found throughout the wall 
(Shepherd, 1987). 
 
 
Figure 2.2 Morphology of (A) pseudohyphae, (B) yeasts and (C) hyphae forms 
(Sudbery, 2011). 
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  Some mycologists prefer to consider the pseudohyphal and hyphal forms 
as one entity; therefore C. albicans is usually said to be dimorphic in nature as it has 
two distinct shapes. Yeast cells are unicellular and spherical or oval in shape, and 
normally form smooth, white dome-shaped colonies. Yeast multiply by a specific 
process of mitotic division known as budding, in which daughter cells exude from the 
mother cells. Several classes of fungi, including C. albicans, are featured with the 
ability to form spores i.e. blastospores and clamydospores (which are spherical, 
smooth surfaced and highly refractile (Nobile et al., 2003), thus more favorable for 
candidal survival). Pseudohyphae are considered modified yeasts which continued in 
polarized growth without separation from the mother cell at the end of each cell cycle 
(Sudbery, Gow, and Berman, 2004). Pseudohyphae are also characterized by unequal 
width of their cellular projections, being wider at the center than at the ends (Merson-
Davies and Odds, 1989). Hyphae are microscopic tubes which contain 
compartmentalized cell units separated by septa, these units arise initially from 
blastospores or also from already existing hyphae (Webb, Thomas, Willcox, Harty, 
and Knox, 1998). When it takes up the hyphal form, it forms filamentous projection 
with parallel sided walls, so keeping the width of their compartments the same 
throughout the branched portion. Germ tube is a term applied to the projecting hyphae 
in the first cell cycle just before septation (Calderone et al., 2000). C. albicans is well 
known for its morphological plasticity, i.e. its ability to transform from one 
morphological pattern to another known as switching, which is thought to promote the 
pathologenicity of the organism (Whiteway and Oberholzer, 2004). There are other 
minor morphological changes which take place during switching. For example, 
opaque phase is a variety where the cell becomes oblong instead of the usual oval 
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form of the yeast. Cell signal transduction pathways and various transcriptional 
effects have been linked to the different array of morphological forms and switching 
of C. albicans (Liu, 2002). 
 2.1.4 Biofilm formation of C. albicans 
  Microorganisms can exist either in a floating planktonic state or attached 
to an external surface. A biofilm is an assembly of surface-coating microbial cells that 
is attached to the surface and enclosed in a matrix of polysaccharide material such as 
alginate, Psl- and Pel-encoded polysaccharide (Donlan, 2002; Ryder, Byrd, and 
Wozniak, 2007). In addition to its association with many hospital acquired 
nosocomial infections, biofilm formation is of clinical significance since it confers the 
associated microorganisms an ability to resist external threats, e.g. antimicrobial drugs 
(Chandra et al., 2001; Shinde, Raut, and Karuppayil, 2012). A biofilm formed of C. 
albicans renders it a hundred times more resistant to the antifungal fuconazole and 
20-30 times more resistant to amphotericin B than planktonic cells (Ramage, Saville, 
Thomas, and Lopez-Ribot, 2005). Both yeast and hyphal forms of C. albicans can 
participate in biofilm formation. Due to biofilm formation, C. albicans yeast is 
considered as one of the most common microorganisms found in the bloodstream in 
hospitalized patients, in whom it originates from the biofilm composed of yeast cells 
embedded in a protective matrix of extracellular protein (Chaffin, Lopez-Ribot, 
Casanova, Gozalbo, and Martinez, 1998; Crump and Collignon, 2000; Soustre, 
Rodier, Imbert-Bouyer, Daniault, and Imbert, 2004). Biofilm of C. albicans has been 
noticed in dentures as well as other biomaterial, e.g. stents, shunts, endotracheal tubes 
and catheters (Andes et al., 2004; Bulad, Taylor, Verran, and McCord, 2004). In order 
to form biofilm C. albicans has to adhere first to a medical device, colonize it and 
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then establish a biofilm. Biofilm formation by C. albicans depends on many factors, 
e.g. nature of the device surface, whether host-derived conditioning film is present 
and liquid flow (Chandra et al., 2001; Kuhn, Chandra, Mukherjee, and Ghannoum, 
2002). Colonization of different biomaterials by C. albicans has been accepted as an 
important major cause of medical device failure (Jones, McGovern, Adair, Woolfson, 
and Gorman, 2001). In the biofilm composed of C. albicans, a layer of yeast cells is 
located lowermost attached to the device. The yeast layer composed of filamentous 
cells in the hyphal form surrounded by extensive exoplasmic matrix (Baillie and 
Douglas, 1999). 
 2.1.5 Epidemiology of C. albicans 
  It is believed that 90% of healthy individuals carry C. albicans if the 
sensitive enough tests were developed. The intraoral commensally living of this 
organism appears at least 50% of the population.  However, it has been shown that 
Candida spp. may heaven more than one species at the same time in hospitalized and 
immunocompromised patients (Odds, 1987). 
  Gastrointestinal (GI) tract is the major environment of the commensal 
Candida spp. It has been shown that, in sufficient high numbers of Candida, C. 
albicans can spread from human gut which causes fungaemia and funguria (Krause, 
Matheis, and Wulf, 1969) and also believed that the gut is the source of the most 
forms of Candida infection (Odds, 1987). 
  From the previous study, it was reported that the prevalence and density 
of C. albicans are greater in edentulous patients, who wear denture, than in normal 
subjects. The dentures have been suggested to help the growth of C. albicans. 
Although the appearance of C. albicans was greater in these patients than in healthy 
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subjects, there was no significant difference in the concentration of C. albicans 
between these groups (Borromeo, McCullough, and Reade, 1992). 
  Candidiasis encompasses infections that range from superficial, such as 
oral thrush and vaginitis, to systemic and potentially life-threatening diseases. 
Candida infections of the latter category are also referred to as candidemia or invasive 
candidiasis, and are usually confined to severely immunocompromised persons, such 
as cancer, transplant and AIDS patients, as well as nontrauma emergency surgery 
patients (Kourkoumpetis et al., 2010). Candidiasis is devided into four types, which 
are mucosal candidiasis, cutaneous candidiasis, onychomycosis, and invasive 
candidiasis. Mucosal candidiasis includes oral candidasis, which is shown as 
pseudomembranous candidosis in Figure 2.3 and denture stomatitis in Figure 2.4 
(Tarcin, 2011). Esophageal candidiasis is also included in mucosal candidiasis as 
shown in Figure 2.5 (Choi et al., 2013). Cutaneous candidiasis includes candidal 
intertrigo, diaper cadidiasis and congenital cutaneous candidiasis. Onychomycosis 
(nail candidiasis) involving the yeasts C. albicans was shown in Figure 2.6 (Nolting, 
Brautigam, and Weidinger, 1994). Invasive candidiasis is infections affecting an ever-
increasing number of hospitalized patients. Invasive candidiasis causes considerable 
morbidity and mortality in patients with medical comorbidities who possess risk 
factors for these infections such as broad-spectrum antibacterial therapy, intense 
myelosuppression and cytotoxic therapies, recent gastrointestinal surgery and the 
presence of central venous access devices. A variety of Candida species may produce 
invasive cadidiasis, but C. albicans continues to be the most common inciting 
pathogen (Bow et al., 2010). Pathogenesis of invasive candidiasis was shown in 
Figure 2.7. 
 
 
 
 
 
 
 
 
 12 
 
Figure 2.3 Pseudomembranous candidosis in a patient using steroid inhaler for 
management of asthma (Tarcin, 2011). 
 
 
Figure 2.4 Denture stomatitis, showing localized erythema of tissues covered by 
dentures (Tarcin, 2011). 
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Figure 2.5 Esophageal candidiasis. (A) Endoscopic finding; multiple whitish plaques 
were identified. (B) Histopathologic finding; esophageal mucosa containing candida 
spores and pseudohyphae were noted (Grocott methenamine silver stain, ×400) (Choi 
et al., 2013). 
 
 
Figure 2.6 Clinical phenotype of the patient with extensive cadidiasis of nails (Uzel et 
al., 2013). 
 
 
 
 
 
 
 
 
 
 14 
 
Figure 2.7 Pathogenesis of invasive candidiasis. Blastospores of Candida gain access 
to the endovascular compartment via gut translocation or endovascular catheter 
colonization (A). Candida blastospores germinate within the bloodstream and interact 
with soluble serum components (B) and circulating neutrophils (C). Organisms then 
adhere to and penetrate vascular endothelial cells (D) to gain access to the deep 
organs, where they interact with dendritic cells and monocyte macrophages (E) that 
activate adaptive immune response (F) (Bow et al., 2010). 
 
 2.1.6 Virulence of C. albicans 
  Among human fungal pathogen, the yeast C. albicans is the major 
opportunistic fungal pathogen of humans. C. albicans lives commensally in humans 
such as at the gut, oral cavity and vaginal mucosa. This microorganism causes 
diseases when given the opportunity. On mucosal surfaces, limitation of nutrient and 
competition surrounded by bacteria and fungi provide selective pressures that result in 
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the elimination of less adapted microorganism. From this competition among mucosal 
bacteria and fungi, the host site (tissue) has specific pressures that a pathogen, such as 
C. albicans, must adapt its growth to a range of physiological extremes such as pH 
(Calderone and Fonzi, 2001). 
  C. albicans expresses several virulence factors include host recognition 
biomolecules (adhesins), morphogenesis (the reversible transition between unicellular 
yeast and filamentous, growth from), secreted aspartyl proteinases (SAPs) and 
phospholipases and probably phenotypic switching (Calderone and Fonzi, 
2001).Successful colonization and infection of host tissues by the pathogenic Candida 
species depend on the ability of these organisms to adhere to mucosal surfaces. A 
hierarchy exists among Candida spp. such that the more commonly presenting 
pathogens, such as C. albicans, adhere to host cells in vitro to a greater extent than the 
relatively nonpathogenic species. This is a clear correlation between adhesion and 
virulence. This correlation has been shown in a comparative study of the adherence of 
different Candida spp. to human epithelial cells (Asakura et al., 1991). 
  The extracellular proteinase activities of C. albicans is associated with 
virulence. Secretory acid proteinase can be shown in patients infected with C. 
albicans. The enzymes produced by these yeasts are carboxyl proteinases capable of 
degrading secretory immunoglobulin A (IgA) which is the major immunoglobulin in 
mucous membrane. Some of these proteinases have keratinolytic or collagenolytic 
activity (Douglas, 1988). The previous investigation suggested that the secretion of 
proteinase is an important factor allowing invasion of the choriollantoic membrane 
(Shimizu, Kondoh, and Tanaka, 1987). 
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 2.1.7 Treatment of C. albicans 
 C. albicans is widely treated with the antifungal agent fluconazole that inhibits 
the biosynthesis of ergosterol. This azole group, include ketoconazole, fluconazole, 
and itraconazole, explain a major advance in systemic antifungal therapy. From these 
azole drugs, fluconazole has the most attractive pharmacologic profile which is the 
capacity to produce high concentrations of active drug in cerebrospinal fluid and 
urine. Ketoconazole is less well tolerated than either fluconazole or itraconazole and 
associated with more important toxic effects, including hepatitis and inhibition of 
steroid hormone synthesis. However, ketoconazole is less expensive than fluconazole 
and itraconazole and it is also important consideration for patients receiving long-term 
therapy. Ketoconazole and itraconazole are effective in patients with the chronic, 
indolent forms of the endemic mycoses, including blastomycosis, histoplasmosis, and 
coccidioidomycosis. Itraconazole is also effective in patients with sporotrichosis and 
it is the most effective of the azoles for the treatment of aspergillosis. Fluconazole is 
useful in the common forms of fungal meningitis--namely, coccidioidal and 
cryptococcal meningitis and it is also effective for selected patients with serious 
candida syndromes such as candidemia (Como and Dismukes, 1994). However, the 
emergence of azole-resistant C. albicans strains is a problem after long-term treatment 
of recurrent oropharyngeal candidiasis (OPC) in acquired immunodeficiency 
syndrome (AIDS) patients (Morschhauser, 2002). 
 Different classes of antifungals are now available to manage any type of 
candidal infection. Azoles, fluconazole in particular (Charlier et al., 2006), have 
become the main stay of therapy over the past few years. This include topical and 
systemic agents. Posaconazole is the most recent addition to this group of antifungals. 
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Polyenes include amphotericin B, liposomal amphotericin B formulations, and topical 
nystatin. Allylamins include terbinafine, which is formulated in a topical preparation 
and an oral tablet. The newest group of antifungals is echinocadins, including 
caspofungin, micafungin, and anidulafugin. These drugs have shown excellent clinical 
efficacy, a low incidence of adverse events, a good safety profile, and ease of use 
(Kauffman, 2006; Sable, Strohmaier, and Chodakewitz, 2008). 
 In addition to azoles, there are another three major groups of antifungal agents 
for clinical use. They are derivatives of echinocadins, polyenes and allylamine of 
which mechanisms will be discussed in the next section. The structures of 
representative antifungal agents, including amphotericin B, fluconazol, terbinafine, 
voriconazol, and echinocandin B, were shown in Figure 2.8.  
 
Figure 2.8 Structures of representative antifungal agents (Ghannoum and Rice, 1999). 
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2.2 Antifungal agents  
 2.2.1 Azole antifungals 
  These agents are synthetic compounds that include two groups, 
imidazole and triazoles. Imidazole agents include miconazole, ketoconazole, and 
clotrimazole. Triazole agents, which are the most commonly used azoles, include 
fluconazole, itraconazole, econazole, terconazole, butonazole, and tioconazole. Newer 
triazoles are active against fluconazole-resistant strains of Candida such as 
voriconazole, posaconazole, and ravuconazole. Voriconazole and posaconazole have 
shown high efficacy against candidiasis in recent clinical trials (Kullberg et al., 2005; 
Ostrosky-Zeichner, Oude Lashof, Kullberg, and Rex, 2003; Skiest et al., 2007). The 
primary mechanism of action is inhibition of lanosterol 14-alpha-demethylase, an 
enzyme required for ergosterol biosynthetic pathway as showed in Figure 2.9 
(Hitchcock, Dickinson, Brown, Evans, and Adams, 1990; Lupetti, Danesi, Campa, 
Del Tacca, and Kelly, 2002). Ergosterol, the primary sterol in the fungal membrane, 
serves as a bioregulator of membrane fluidity in fungal cells (Ellis, 2002; Espinel-
Ingroff and Shadomy, 1989). 
  Inhibition of 14α-demethylase leads to depletion of ergosterol and 
accumulation of sterol precursors, including 14α-demethylated sterol (lanosterol, 
4,14-dimethylzymosterol, and 24-methylenedihydrolanosterol). These result in an 
alteration of the structure and function of plasma membrane. The recent triazole 
derivatives, such as fluconazole, itraconazole, and voriconazole, have their own 
antifungal activity at least in part to inhibition of cytochrome P-450-dependent 14α-
sterol demethylase (Sanati, Belanger, Fratti, and Ghannoum, 1997). 
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Figure 2.9 Mechanism of action of antifungal drugs affecting the ergosterol 
biosynthetic pathway. Steps at which various antifungal agents exert their inhibitory 
activities are shown (Lupetti et al., 2002). 
 
  Although more recent azole antifungals are 14α-demethylase inhibitors, 
there exists a heterogeneity of action among these antifungals (Beggs, 1983; Sud and 
Feingold, 1981). The imidazole derivatives, such as miconazole, econazole, and 
ketoconazole, have a complex mode of action, inhibiting several membrane-bound 
enzymes as well as membrane lipid biosynthesis (Sheehan, Hitchcock, and Sibley, 
1999). In Candida krusei, voriconazole significantly inhibited ergosterol synthesis. 
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The C. krusei cells treated with voriconazole accumulated the following biosynthetic 
intermediates: squalene, 4,14-dimethylzymosterol, and 24-methylenedihydrolano- 
sterol. Accumulation of these methylated sterols is consistent with the premise that 
this agent functions by inhibiting fungal P-450-dependent 14α-demethylase (Sanati et 
al., 1997). 
  Azole activity may possess organism-dependent fungicidal activities 
(Manavathu, Cutright, and Chandrasekar, 1998). In addition to inhibiting the 14α-
demethylase in Cryptococcus neoformans, fluconazole and itraconazole affect the 
reduction of obtusifolione to obtusifoliol, which results in the accumulation of 
methylated sterol precursors (Ghannoum et al., 1994; Van den Bossche et al., 1993). 
Mammalian cholesterol synthesis is also blocked by azoles at the stage of 14α-
demethylation. However, the dose required to affect the same degree of inhibition is 
much higher than that required for fungi (Hitchcock et al., 1990; Van den Bossche, 
Willemsens, Cools, Lauwers, and Le Jeune, 1978). The clinical effects of inhibition of 
human sterol biosynthesis are most prominently seen with ketoconazole (Ghannoum 
and Rice, 1999). Moreover, the accumulation and importation of fluconazole was 
tested in the pathogenic fungus, such as C. albicans. These antifungal agents import 
via facilitated diffusion through a transporter rather than passive diffusion. The other 
fungi, including C. neoformans, Saccharomyces cereviciae, and C. krusei, have been 
observed on import of fluconazole by facilitated diffusion (Mansfield et al., 2010). 
 2.2.2 Mechanisms of resistance to azoles 
  Several lines of evidence implicate a modification in the quantity or 
quality of 14α-demethylase in the expression of resistance to azole antifungal agents. 
A recent study examined the biochemical mechanisms for resistance to fluconazole by 
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comparing sterol composition, fluconazole accumulation, and inhibition of 14α-
demethylase by fluconazole in two clinical C. krusei strains and a susceptible isolated 
C. albicans. The sterol content of C. krusei and C. albicans were detected (ergosterol 
was the major sterol in both species) and also performed on cell extracts indicated that 
the fluconazole concentration required to inhibit the synthesis of ergosterol 
approximately 24 to 46-fold higher in C. krusei than in C. albicans, advising that 
affinity of the target enzyme is different in the two species (Orozco et al., 1998). A 
comparison of fluconazole accumulation between C. albicans and C. krusei showed 
that fluconazole accumulation in the first 60 min was not different from all studied 
strains. However, the analysis after 90 minutes of the incubation displayed that C. 
krusei accumulated 60% less fluconazole accumulation than did C. albicans, 
suggesting active efflux in the fluconazole resistance expressed by these C. krusei 
strains. 
  Other studies have showed an alteration of 14α-demethylase activity in 
resistance to azoles. Reduced susceptibility of C. albicans B41628 to miconazole, 
ketonazole, itranazole, and fluconazole was attributed to differences in the 
microsomal cytochrome P-450 enzyme (Smith et al., 1986; Sokol-Anderson, 
Brajtburg, and Medoff, 1986). In addition, the enzyme had a low binding affinity for 
azole antifungal (Van den Bossche, Willemsens, Cools, Marichal, and Lauwers, 
1983). 
  Overexpression of 14α-demethylase has been involved as a mechanism 
of resistance to azole antifungals. The characterization of an azole-resistant C. 
glabrata had been isolated and showed that its ergosterol content was increased when 
compared with pretreatment isolate. This increase in ergosterol synthesis suggested 
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that both lower fluconazole uptake and increased P-450-dependent ergosterol 
synthesis are involved in the mechanism of fluconazole resistance, suggesting an 
overexpression of the enzyme (Van den Bossche, Marichal, Odds, Le Jeune, and 
Coene, 1992). It has been suggested that the increased P-450 levels may be 
responsible for the cross-resistance to these triazoles. 
  Considerable evidence has now been accumulated to suggest that active 
efflux is an important mechanism of resistance to azole antifungals. A group of 
researchers have reported that fungi possess at least two efflux systems: (1) proteins 
belonging to the major facilitator super family (MFS) and (2) ATP-binding cassette 
(ABC) superfamily of proteins. The MFS drug efflux proteins are associated with the 
transport of structurally diverse compounds and accounted for a range of resistance to 
toxic compounds in microorganisms (Jenkinson, 1996) 
  Alteration in membrane composition had been studied in an interaction 
between sterols and phospholipids in the cytoplasmic membrane. Using cerulenin as a 
lipid modulator showed that altered phospholipids and fatty acid profiles affected C. 
albicans cell permeability and rendered the cells more resistant to miconazole (Mago 
and Khuller, 1989). A decrease in the amount of drug taken up by the fungal cell was 
suggested to be a result from changes in the sterol and/or the phospholipids 
composition of the fungal cell membrane. 
  It has been shown that an azole-resistant and polyene-resistant C. 
albicans mutant had a larger lipid content and lower polar-lipid-to-neutral-lipid ratio 
than did strains susceptible to azoles. However, the most significant change in the 
lipid of the resistant strain was in the membrane sterol pattern, where ergosterol was 
replaced by methylated sterols, such as methylfecosterol (Hitchcock, Barrett-Bee, and 
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Russell, 1987). The summary of mechanisms by which microbial cells might develop 
resistance as showed in Figure 2.10. 
 
Figure 2.10 Mechanisms by which microbial cells might develop resistance 
(Ghannoum and Rice, 1999). 
 
  Figure 2.10 demonstrates the postulated mechanisms of resistance to 
antifungal. First, the target enzyme is overproduced, so that the drug does not inhibit 
the biochemical reaction completely. Secondly, the drug target is altered so that the 
drug cannot bind to the target. Thirdly, the drug is pumped out by an efflux pump. 
Fourthly, the entry of the drugs is prevented at the cell membrane/cell wall level. The 
fifth mechanism is that the cell has a bypass pathway that compensates for the loss-of-
function inhibition due to the drug activity. Some fungal enzymes that convert an 
inactive drug to its active form are inhibited. The last is that the cell secretes some 
enzymes to the extracellular medium, which degrade the drug (Ghannoum and Rice, 
1999). 
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 2.2.3 Glucan synthesis inhibitors (Echinocadins) 
  Echinocadins inhibit the synthesis of (1,3) β-D-glucan, an essential 
component of the fungal cell wall. This component is not found in mammalian cell 
wall. These agents have expanded with the approvals of caspofungin, micafungin, and 
anidulafungin. Indication are evolving but have been approved for complicated forms 
of invasive candidiasis, candidemia, disease refractory to other systemic antifungals, 
and intolerance to amphotericin B. They are board spectrum and fungicidal against 
most Candida species, except C. parapsilosis and C. guilliermondii.  
 2.2.4 Polyenes 
  These are board-spectrum fungicidal agents. Mechanism of action is by 
insertion into fungal cytoplasmic membrane, causing increases in permeability. 
Membrane channel activity is increased at lower dose, and pores are formed at higher 
concentration. The polyene class of antifungals includes amphotericin B, nystatin, and 
natamycin. All organisms susceptible to polyenes, e.g. yeasts, algae, andprotozoa, 
contain sterols in their outer membrane, while resistant organisms do not susceptible 
to polyenes (Norman, Demel, de Kruyff, Geurts van Kessel, and van Deenen, 1972). 
For larger polyenes, such as amphotericin B, it has been proposed that the interaction 
of the antifungal with membrane sterol results in the production of aqueous pores 
consisting of an annulus of eight amphotericin B molecules linked hydrophobically to 
the membrane sterols (de Kruijff and Demel, 1974; Holz, 1974) as showed in Figure 
2.11. This configuration gives rise to a pore in which the polyene hydroxyl residues 
face inward, leading to altered permeability, leakage of vital cytoplasmic components, 
and death of the organism. Moreover, amphothericin B in the concentration of 1.25 to 
 
 
 
 
 
 
 
 
 25 
10 µg/ml killed both Aspergillus fumigates and C. albicans (Manavathu, Cutright, and 
Chandrasekar, 1998). 
 
 
Figure 2.11 The interaction between amphotericin B and cholesterol in a 
phospholipid bilayer. (A) The conducting pore is formed by the end-to-end union of 
two wells or half pores. (B) Molecular orientation in an amphotericin B-cholesterol 
pore. The dotted lines between the hydrocarbon chains of phospholipids represent 
short-range van der Waals forces. The dashed lines represent hydrogen bonds formed 
between amphotericin B and cholesterol molecules (Ghannoum and Rice, 1999). 
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 2.2.5 Mechanism of resistance to polyenes 
  Most of the mechanisms of resistance to polyenes in fungal species have 
come from studies using mutants generated by (1) growing cells in the presence of 
increasing concentrations of antifungal agents, (2) exposing the cells to a gradient 
concentration (Athar and Winner, 1971), or (3) creating mutants by one-step mutation 
with mutagenic agents (Hamilton-Miller, 1972). It is postulated that the resistant cells 
with altered sterol content bind smaller amounts of polyene than do susceptible cells. 
This decreased binding of polyenes in C. albicans mutants could be attributed to (1) a 
decrease in the total ergosterol content of the cell, without concomitant changes in 
sterol composition; (2) replacement of some or all of the polyene-binding sterols by 
ones which bind polyene less well, e.g., substitution of ergosterol, cholesterol, or 
stigmasterol by a 3-hydroxy or 3-oxosterol; or (3) reorientation, or masking, of 
existing ergosterol, so that binding with polyenes is sterically or thermodynamically 
less favored (Michaelis and Berkower, 1995). 
 2.2.6 Allylamines 
  Allylamines, such as terbinafine and naftifine, have been developed as a 
new class of ergosterol biosynthetic inhibitors that are functionally as well as 
chemically distinct from the other major classes of ergosterol-inhibiting antifungal 
agents. Terbinafine is highly effective against dermatophytes in vivo and in vitro. 
Terbinafine has good activity against at least some azole-resistant C. albicans strains 
(Ghannoum and Rice, 1999). Allylamines act by inhibiting early steps of ergosterol 
biosynthesis, suggesting that allylamine inhibition of sterol synthesis occurs at the 
point of squalene epoxidation, a reaction catalyzed by squalene epoxidase, causing 
fungal-cell death (Birnbaum, 1990). 
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 2.2.7 Mechanism of resistance to allylamines 
  Although clinical failure has been observed in patients treated with 
terbinafine, allylamine resistance in association with clinical use of terbinafine and 
naftifine has not been found in human pathogenic fungi. However, with the increased 
use of this agent, resistance may be expected, since it was reported that a C. glabrata 
strain that became resistant to fluconazole expressed cross-resistance to terbinafine 
(Van den Bossche et al., 1992). 
 
2.3 Alpinia officinarum Hance (Lesser galangal) 
 2.3.1 General background of A. officinarum 
  Alpinia officinarum Hance, known as lesser galangal, is of Zingiberaceae 
family and Alpinia genus. It is a pungent and aromatic rhizome, cultivated in several 
countries in Asia such as China, Vietnam and Thailand. It is used as a spice ingredient 
for flavoring food throughout southeast Asian countries (Ly, Shimoyamada, Kato, and 
Yamauchi, 2003; Ly, Yamauchi, Shimoyamada, and Kato, 2002). The dried rhizome 
of A. officinarum has been used as a popular traditional herbal medicine for several 
purposes, such as relieving stomachache, treating colds, strengthening the circulatory 
system, and reducing swelling (An et al., 2008; Seddeag, Madawe, Badwi, and 
Bakhiet, 2010). 
  Lesser galangal has a pungent and spicy taste. It grows to a height of 
about 5 feet. The leaves are long and rather narrow blades. The flowers are grown in 
terminal spike. The petals are white, with deep-red veining distinguishing the lippetal. 
The most commonly used part is its rhizome. The branch pieces of rhizome are from 
1.5 to 3 inches in length with a reddish-brown color (Grieve, 1995-2013). Figure 2.12 
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and 2.13 are the morphological features of rhizome, leaves and flowers of A. 
officinarum.  
 
 
Figure 2.12 Aboveground and underground portion of Alpinia officinarum (Grieve, 
1995-2013). 
 
 
Figure 2.13 Lesser galangal (Alpinia officinarum) appearing in nature. 
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 2.3.2 The chemistry of A. officinarum 
  In the chemical studies of the rhizomes, the isolation and structure 
determination of monoterpenes, diarylheptanoids, flavonoids, phenylpropanoids, and 
neolignans have been reported. The constituents isolated from A. officinarum 
rhizomes consist of a diarylheptanoid [7-(4"-hydroxy-3"-methoxyphenyl)-1-
phenylhept-4-en-3-one (2) ], flavonols [kaempferide (5), galangin (6)], 5-Hydroxy-
1,7-diphenyl-3-heptanone (1), 5-hydroxy-7-(4"-hydroxy-3-methoxyphenyl)-1-phenyl-
3-heptanone (3), and 3,5-dihydroxy-1,7-diphenylheptane (4) (Matsuda, Nakashima, 
Oda, Nakamura, and Yoshikawa, 2009). Their structures were presented in Figure 
2.15. 
 
Figure 2.14 Chemical structures of compounds isolated from the rhizomes of A. 
officinarum (Matsuda et al., 2009). 
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 2.3.3 The biological activity of A. officinarum 
  A. officinarum has been shown to possess many biological activities. It 
showed an activity against 5alpha-reductase (Kim et al., 2003) and also showed 
moderate cytotoxicity against several human tumor cell lines, including HepG2, 
MCF-7 and SF-268 (An et al., 2008). The rhizomes of A. officinarum posses anti-
inflammatory, anti-nociceptive, and anti-psychiatric activities (Lee et al., 2009). The 
crude extract of the rhizomes of A. officinarum as well as its bioactive components 
have been shown to possess antioxidant and antibacterial activities (Srividya, 
Dhanabal, Misra, and Suja, 2010; Zhang, Dai, Liao, and Ding, 2010). 
  The rhizomes of A. officinarum have been shown anti-inflammatory 
effect by inhibiting nitric oxide (NO) production in lipopolysaccharide (LPS)-
activated macrophages (Lee et al., 2009; Matsuda, Ando, Kato, Morikawa, and 
Yoshikawa, 2006). Nitric oxide (NO), involved in inflammation, is produced and 
released by induction of inducible nitric oxide synthase (iNOS), resulting in 
cytotoxicity, and tissue and DNA damage (Raso, Meli, Di Carlo, Pacilio, and Di 
Carlo, 2001). Moreover, this plant showed anti-rheumatic and analgesic activities by 
suppressing the swelling volume and inhibiting the flexion scores in complete 
Freund’s adjuvant which stimulated arthritis (Lee et al., 2009). 
  Some glycosides and anti-oxidative compounds from A. officinarum 
rhizomes have been separated and identified (Ly et al., 2003; Ly et al., 2002). The 
rhizomes of A. officinarum were found to have potent antibacterial, antioxidant (Ly, 
Shimoyamada, Kato, and Yamauchi, 2004; Srividya et al., 2010) and anti-genotoxic 
activities (Heo, Sohn, and Au, 2001). This plant contains several potent enzyme 
inhibitors. For example, it has been shown that they block pancreatic lipase (Shin, 
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Han, and Kim, 2003), 5α-reductase (Kim et al., 2003) and enzymes that involved in 
arachidonate inflammatory pathway,  prostaglandin synthetase and 5-lipoxygenase 
(Kiuchi, Iwakami, Shibuya, Hanaoka, and Sankawa, 1992). In addition, 
diarylheptanoids from A. officinarum has been reported to correlate to the inhibition 
of nitric oxide (NO) production in lipopolysaccharide-activated macrophages 
(Matsuda et al., 2006). The acetone extract from rhizomes of A. officinarum was 
shown to inhibit melanogenesis in theophylline-stimulated murine B16 melanoma 
(Matsuda et al., 2009). Several compounds isolated from A. officinarum have shown 
the property of combating nausea (Shin, Kinoshita, Koyama, and Takahashi, 2002). 
  Galangin, a member of flavonol class of flavonoids, is present in high 
concentrations in A. officinarum (Heo, Sohn, and Au, 2001). Galangin, isolated from 
A. officinarum rhizomes, is a topic of interest because it has been shown to possess 
many pharmacological activities. It showed an inhibitory effect on 
acetylcholinesterase (AChE) activity (Guo et al., 2010). Because AChE inhibitors are 
widely used for Alzheimer’s disease treatment, it is suggested that the flavonoid 
galangin from rhizomes of A. officinarum may has potential for development of anti-
Alzheimer agents. Galangin may be a useful chemopreventive compound due to its in 
vivo potent anticlastogenic effects (Heo, Jae, Jung, and Au, 1996). Galangin also 
possess anti-microbial activities. Antibacterial activity of galangin against 4-
quinolone resistant strains of Staphylococcus aureus have been demonstrated 
(Cushnie and Lamb, 2006). Moreover, the combination of galangin with gentamycin 
showed synergism against Methicillin-Resistant S. aureus (Lee et al., 2008). 
However, antifungal, especially anticandidal, activity of this plant has not been 
reported. 
 
 
 
 
 
 
 
 
 CHAPTER III 
MATERIALS AND METHODS 
 
3.1 Chemical sources 
 All chemicals were purchased from various suppliers (Carlo Erba, Himedia, 
Merck, and Sigma-Aldrich) as listed in Table 3.1. 
 
Table 3.1 List of used chemicals. 
Chemicals Supplier 
Acetone Carlo Erba, Italy 
D-Glucose Carlo Erba, Italy 
Ethanol Carlo Erba, Italy 
Ethyl acetate Carlo Erba, Italy 
Galangin Sigma-Aldrich, USA 
Ketoconazole Sigma-Aldrich, USA 
Methanol Carlo Erba, Italy 
Peptone Himedia, India 
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Table 3.1 List of used chemicals (Continued). 
Analytical grade chemicals Supplier 
Acetone Carlo Erba, Italy 
Hexane 
Carlo Erba, Italy 
HPLC grade chemicals Supplier 
Methanol 
Sigma-Aldrich, USA 
Phosphoric acid Sigma-Aldrich, USA 
 
 Silica gel 60 F254 precoated TLC aluminum sheet (20 × 20 cm
2
 in size with 
layer thickness of 0.2 mm) was purchased from Merck, USA. Standard galangin was 
bought from Sigma-Aldrich, USA. 
 
3.2 Plant material 
 A. officinarum was bought from local markets in Nakhon Ratchasima province, 
Thailand. The rhizomes of lesser galangal were separated from the stem, washed 
thoroughly, and oven dried at 50 C for 3 days. The sample was then grounded to 
powder and kept in -20 C until used. The dried rhizomes of A. officinarum (300 g) 
were extracted with 1500 ml of 80% aqueous acetone three times at room 
temperature. The extracted solutions were filtered through filter paper (Whatman 
No.1). The filtrate was concentrated by evaporation under reduced pressure to obtain 
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a semisolid material, which was then lyophilized by freeze dryer. The extract (yield: 
3.24%) was kept at -20 C until used. 
 
3.3 Extraction 
 The rhizomes of lesser galangal were separated from the stem, washed 
thoroughly, and oven dried at 50 C for 3 days. The sample was then grounded to 
powder and kept in -20 C until used. The dried rhizomes of A. officinarum (300 g) 
were extracted with 1500 ml of 80% aqueous acetone three times at room 
temperature. The extracted solutions were filtered through filter paper (Whatman 
No.1). The filtrate was concentrated by evaporation under reduced pressure to obtain 
a semisolid material, which was then lyophilized by freeze dryer. The extract (yield: 
3.24%) was kept at -20 C until used. The extraction is shown in Scheme 3.1. 
 
Scheme 3.1 Extraction of the rhizomes of lesser galangal. 
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3.4 Antifungal susceptibility testing 
 Antifungal activity of lesser galangal against C. albicans was evaluated using 
agar disc diffusion method. One hundred microliters of fresh culture suspension 
(1×10
6
 cells/ml) of C. albicans was spread on SDA plates. Sterile filter paper discs   
(5 mm diameter) were impregnated with 10 l of A. officinarum extract (250 µg/disc) 
or galangin (50 µg/disc). After dried, the discs were placed on the surface of the 
inoculated SDA plates. The plates were incubated at 30 C for 24 h. Clear inhibition 
zone around the discs indicated the presence of antifungal activity. All the tests were 
performed in triplicate with ketoconazole (15 µg/disc) as positive control and 10 l of 
5% dimethyl sulfoxide (DMSO) (v/v) as vehicle control. 
 
3.5 Determination of minimum inhibitory concentration 
 The starter of C. albicans cultures was prepared by inoculation of the stock 
culture in fresh Sabouraud dextrose broth (SDB) and incubated for 24 h at 30 C on a 
rotary shaker (200 rpm). The cultures were transferred to fresh SDB in dilution 1:100 
and further incubated for 12 h due to the growth profiles of C. albicans are shown in 
Figure 3.1.  
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Figure 3.1 Growth profiles of C. albicans incubated at 30C. 
 
 After 12 hours of incubation, the concentration of 1×10
6
 cells/ml, standardized 
spectrophotometrically to an absorbance of 2.50 at 600 nm, was used for testing 
minimum inhibitory concentration (MIC). 
 The concentration of crude extract at 50 mg/ml was used as stock solution in 
DMSO. Three milliliters of SDB containing various concentrations of the extract and 
30 µl of C. albicans (10
6
 cells/ml) were mixed in test tube and incubated at 30 °C. 
The growth of C. albicans was spectrophotometrically monitored. The MIC is defined 
as the lowest concentration that inhibits the growth of C. albicans at the end of 24 h of 
incubation. 
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3.6 Determination of minimum fungicidal concentration 
 Based on the result from MIC method, cells from the tubes showing no growth 
were subcultured on SDA plates and incubated at 30 C for 24 hours. The MFC is 
defined as the lowest concentration that causes total inhibition of visible growth of C. 
albicans at the end of 24 hours of incubation. All the tests were done in three 
replicates. 
 
3.7 Isolation of galangin from the extract by thin layer 
chromatography (TLC) 
 Two hundred and fifty micrograms of the crude extract were applied to silica 
gel 60 F254 for fingerprint compared to standard galangin (0.5 g). The plates were 
developed in mobile phase of hexane and ethyl acetate (7:3) and visualized under UV 
light at 254 nm. 
 
3.8 Quantitative analysis of galangin in the extract of A. 
officinarum by high-performance liquid chromatographic (HPLC) 
method 
 The amount of galangin in the acetone extract from rhizomes of A. officinarum 
was examined by high performance liquid chromatographic (HPLC). The HPLC 
system was equipped with the Waters 600 HPLC system. Separation was performed 
on a reverse phase column (Novapack ODS, 5 µm, 4.6×250 mm) provided with C18 
guard column (C18 Waters, MA, USA) and methanol-water-phosphoric acid 
(60:38:2) were used as the mobile phase. The flow rate was constantly kept at 0.8 
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ml/min and peaks were identified by using UV absorbance at 254 nm. The 
temperature of the column during analysis was maintained at 40 C and the volume of 
10 µl of the sample was injected each time. 
 
3.9 Determination of inhibition of growth by bioautography 
 For bioautographic analysis, developed TLC plates were carefully dried for 
complete removal of solvent, overlaid with agar containing an aliquot of C. albicans 
culture (10
6
 cells/ml) and incubated at 30 ºC for 24 h. The areas of inhibition were 
compared with the retention factor (Rf) of the galangin. The clear zones indicated the 
presence of compounds in the extract that inhibited the growth of C. albicans. 
 
3.10 Scanning electron microscopy (SEM) 
 Scanning electron microscopy (SEM) was performed on C. albicans cells. C. 
albicans cells at the concentration of 1×10
6
 cells/ml were added into 3 ml of SDB and 
incubated at 30 ºC. After incubated for 24 h, C. albicans cells were treated with the 
crude extract of A. officinarum at the concentration of 0.8, 1.2, 1.6 and 2.0 mg/ml and 
then incubated for further 36 h. The DMSO-treated culture was used as vehicle 
control. Cell pellets were fixed with 2.5% glutaraldehyde in carcodylate buffer 
overnight and washed three times in 0.1 M carcodylate buffer solution (pH 7.2). Then, 
the cells were post fixed with 1% osmium tetroxide (OsO4) in 0.1 M carcodylate 
buffer solution (pH 7.2) for 1 h and washed again with 0.1 M carcodylate buffer 
solution (pH 7.2) for 15 minutes three times. Then each suspension was serially 
dehydrated with 30%, 50%, 75%, 90% and 100% ethanol for 15 minutes each. Then 
the cells were freeze dried in critical point dryer. The dried cells were coated with 
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gold for SEM study. The analytical condition for SEM was as the following: L = SE1, 
WD = 17 mm, and EHT = 10.0 kV. 
 
3.11 Biofilm assay 
Many types of materials have been used for growing Candida biofilms in 
vitro, including polystyrene (Kuhn, Chandra, Mukherjee, and Ghannoum, 2002; 
Tarcin, 2011), polyvinyl chloride (Hawser and Douglas, 1994), silicone elastomer and 
polymethylmethacrylate (Chandra et al., 2001). Although polystyrene is not a 
material used in indwelling medical devices, it has been used widely for in vitro 
diagnostics and shown to be an excellent material for promoting adherence of cells. In 
addition, a standardized method for biofilm formation based on polystyrene 96-well 
plates has been established (Li, Yan, and Xu, 2003). But in this study polystyrene 24-
well plates has been used. 
3.11.1 Direct microscopic analysis  
The inhibitory effect of the extract on biofilm formation was examined 
by microscopic analysis. C. albicans was cultured in SDB at 30 C for 24 h. The C. 
albicans starter (30 l) was pipette into each well of 24-well plates in the presence of 
3 ml SDB and incubated at 37 °C for 9 h (adhesion period). Supernatant including 
planktonic cells was then discarded and wells were gently washed twice with PBS to 
get rid of any non-adherent cells. For inhibition of biofilm growth, the crude extract 
was then added to each well in the final concentrations of 0.8, 1.2, 1.6 and 2.0 mg/ml. 
The plates were covered, wrapped with parafilm to prevent evaporation and incubated 
at 37 °C for further 48 h. After the incubation period, planktonic cells were discarded 
through three rounds of washing with 2 ml sterile PBS buffer. DMSO-treated cells 
 
 
 
 
 
 
 
 
 40 
were used as vehicle control. The inhibitory effect on biofilm formation was observed 
under phase contrast microscope.  
 3.11.2 Spectroscopic examination  
Biofilm formation was prepared using the same method described in 
section 3.11.1. After treated with the extract for 48 h, the medium and non-adherent 
cells were removed from wells and washed three times with sterile phosphate buffer 
solution (PBS) and dried in the room temperature for 15 minutes. Then 1% crystal 
violet was added to stain the biofilms in the wells. After that the unadsorbed stain 
were removed by washing with PBS 3 times. The wells were destained by 2 ml of 
ethanol and the destained solution was transferred to a new plate. Optical density of 
cells was determined for each suspension at 590 nm (Benchmark Plus Microplate 
spectrophotometer, Bio-Rad, USA).  
 
3.12 Statistical analysis 
Data are expressed as mean ± S.D. Comparison among different groups was 
performed by analysis of variance (ANOVA) followed by Student-Newman-Keuls 
test. P- values less than 0.05 were set as the level of significance. 
 
 
 
 
 
 
 
 
 CHAPTER IV 
RESULTS  
 
4.1 Antifungal activity of A. officinarum extract 
 By disc diffusion method, 250 g of the extract and 15 g of ketoconazole 
(positive control) produced 11.0 and 23.0 mm diameter of inhibition zone (Table 4.1), 
respectively, whereas 100 g of galangin produced only 8 mm diameter of clear zone. 
These results indicated that both galangin and the extract possessed antifungal effect 
against C. albicans with lower potency than ketoconazole.  
 
Table 4.1 Antifungal activity of A. officinarum rhizome extract against C. albicans. 
Microorganism 
Diameters of inhibition zone (nm) Positive control 
The extract (250 g) Galangin (100 g) Ketoconazole (15 g) 
C. albicans 11.0 ± 1.0 8.0 ± 1.0 23.0 ± 1.0 
 
4.2 Isolation and quantitative analysis of galangin in the extract of 
A. officinarum 
 To further investigate whether galangin was accountable for anticandidal 
activity, the content of galangin in the extract was determined. At first, 80% acetone 
crude extract was subjected to HPLC analysis, however it was found that the crude 
extract of A. officinarum contained relatively low concentration of galangin which 
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could not be detected by HPLC as shown in Figure 4.1A. Figure 4.1B represented a 
typical HPLC chromatogram of galangin standard (retention time: 23.4 min). In order 
to increase its concentration in the sample, galangin was isolated from the crude 
extract by TLC. Figure 4.2 showed that galangin was isolated from the crude extract 
co-migrating with galangin standard. The scraped area was eluted with acetone and 
then the acetone extract from the scraped silica gel was reanalyzed by HPLC (Figure 
4.3) and calculated for its concentration. The result showed that the content of 
galangin in the extract was 3.8 mg/g crude extract. 
 
4.3 Bioautography detection in TLC 
 Bioautography, a microbiological screening method, is commonly used for the 
detection of antimicrobial activity. In this study, bioautography was conducted to 
investigate whether galangin was the active ingredient responsible for anticandidal 
activity of A. officinarum extract. First, 250 g of A. officinarum extract was 
separated by solvent system (hexane, ethyl acetate (7:3) on TLC (Figure 4.4). From 
bioautography analysis, it was found that 10 g of galangin which is about 10 times 
more than the equivalent dose of galangin in the extract (0.85 g/250 g) showed no 
effect on candidal growth. The clear zone on bioautograph of the extract appeared on 
the spotting position as shown in Figure 4.5.  
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Figure 4.1 HPLC chromatograms of A. officinarum extract (A) and standard galangin 
(B). Panel A showed no detectable peak at the retention time of 23.4 min. In panel B,  
A-D are standard galangin at the concentration of 0.01, 0.025, 0.05 and 0.1 mg/ml, 
respectively. 
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Figure 4.2 The scraped area from TLC. Lane A is the galangin standard (10 g) 
whereas lane B is the extract of A. officinarum (250 g). 
  
 
Figure 4.3 HPLC chromatogram of the acetone extract from silica gel. Galangin was 
detected at the retention time of 23.4 min and the calculated concentration was 3.38 
mg/g extract. 
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Figure 4.4 Representative image of TLC plates of the A. officinarum extract. The 
observation was done at 254 nm along with the standard galangin. 
 
 
Figure 4.5 TLC-direct bioautograph of A. officinarum extract against C. albicans.  
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4.4 Minimum inhibitory concentration (MIC) of the extract 
 The MIC is defined as the lowest concentration that inhibits the growth of C. 
albicans at the end of 24 h of incubation. The inhibitory effect of lesser galangal on C. 
albicans is shown in Figure 4.6. It was found that the extract exhibited antifungal 
activity against C. albicans with MIC at 1.2 mg/ml. 
 
Figure 4.6 The inhibitory effect of lesser galangal on growth of C. albicans (n = 3). 
 
4.5 Minimum fungicidal concentration (MFC) of the extract 
 The MFC is defined as the lowest concentration that causes total inhibition of 
visible growth of C. albicans at the end of 24 h of incubation. It was found that the 
MFC value of the extract was 2.0 mg/ml.  
 
4.6 Morphological changes observed by SEM 
 In order to investigate a mechanism underlie the antifungal activity of the 
extract, scanning electron microscopy (SEM) was conducted. SEM analysis showed 
that the extract induced deformation of C. albicans in dose-response manner. Figure 
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4.8 showed that cell changed from smooth (Figure 4.8A: untreated cells) to coarse 
surface when treated with low doses as shown in Figure 4.8C, 4.8D and 4.8E, and 
from oval to rounder shape when treated with higher dose (MFC) as shown in Figure 
4.8F. 
 
 
Figure 4.7 MFC of the extract on C. albicans. A: untreated C. albicans, B-D: cells 
treated with 1.2, 1.6 and 2.0 mg/ml extract, respectively. There was no fungal growth 
on the plate treated with the extract at the concentration of 2.0 mg/ml (panel D). 
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Figure 4.8 SEM micrographs of C. albicans treated with the extract of A. officinarum. 
Cells were treated as described in Materials and Methods. Coarse surfaces of the 
damaged cells were seen in the cells treated with the extract at 0.8 (C) and 1.2 mg/ml 
(D), and more clearly seen in higher concentration (E: 1.6 mg/ml). The cell treated 
with MFC at 2.0 mg/ml (F) of A. officinarum extract changed from oval to rounder 
shape. 5% DMSO (B) did not affect morphology of the candidal cells compared to 
control (A). 
 
4.7 Effect of the extract on biofilm formation 
 Crystal violet staining of surface-attached cells by microtiter plate assay is a 
convenient method for quantitative detection of C. albicans biofilm formation (Kuhn, 
Chandra, Mukherjee, and Ghannoum, 2002). In this study the effect of the extract on 
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biofilm formation was investigated by direct microscopic analysis and spectroscopic 
determination at 590 nm. Figure 4.9 showed phase contrast microscopic images of C. 
albicans treated with various concentrationa of A. officinarum extract. It was found 
that C. albicans formed vast empty regions on plate surface with clusters of cells 
when treated with the extract at the concentration of 0.8 (C), 1.2 (D), 1.6 (E) and 2.0 
(F) mg/ml compared to control (A) and DMSO-treated cells (B). In accordance, the 
result from spectroscopic measurement as shown in Figure 4.10 revealed that A. 
officinarum extract had inhibitory effect on biofilm formation in dose-dependent 
fashion.  
 
Figure 4.9 Microscopic images on biofilm formation of C. albicans treated with A. 
officinarum extract. Cells treated with the extract at the concentration of 0.8 (C), 1.2 
(D), 1.6 (E) and 2.0 mg/ml (F) formed less biofilm than sample (A) and DMSO-
treated cells (B). 
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Figure 4.10 The inhibitory effect of the extract on C. albicans biofilm by 
spectroscopic analysis.
 a, b,
 and 
c
 statistically significant difference from control, 0.8 
and 1.2 mg/ml, respectively (p < 0.05). 
 
 
 
 
 
 
 
 
 CHAPTER V 
DISCUSSION AND CONCLUSION 
 
 The various therapeutic effects of lesser galangal such as anti-emetic, anti-
inflammatory, anti-nociceptive, anti-psychiatric, anticancer and antioxidant activities, 
have been previously reported (An et al., 2008; Lee et al., 2009; Shin, Kinoshita, 
Koyama, and Takahashi, 2002; Zhang, Dai, Liao, and Ding, 2010). The antibacterial 
activities of A. officinarum have also been documented by several groups of 
researchers. For example, Huang and coworkers (Huang, Wu, Tian, Ma, and Wu, 
2008) showed that 40% ethanolic extract of the rhizomes of A. officinarum  possessed 
antibacterial activity against Staphylococcus aureus, hemolytic streptococcus and S. 
pneumonia. Moreover, a group of investigators from India found that galangal 
extracts by three different methods showed moderate to potent antimicrobial activity 
against Bacillus cereus, S. aureas, Pseudomonas auroginosa, and Escherichia coli  
(Srividya, Dhanabal, Misra, and Suja, 2010). Active compounds of A. officinarum  
rhizomes which are responsible for antimicrobial activities have been identified. 
Diarylheptanoids have been isolated and shown that they strongly inhibit growth of 
Helicobactor pylori (Zhang et al., 2010). The flavonol galangin has been reported to 
be a major component of A. officinarum (Cushnie and Lamb, 2006) as well as several 
other medicinal natural products including Helichrysum aureonitens and propolis 
(Patel, Patel, Gadewar, and Tahilyani, 2012). Data from several studies suggested that 
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galangin be responsible for the antibacterial activity of natural products from plants 
(Cushnie and Lamb, 2006).  
 In the present study, antifungal activity of A. officinarum rhizome extract 
against C. albicans was evaluated. Contrary to the previous study reported by 
Srividya and colleagues (Srividya et al., 2010), it was found that 80% acetone extract 
of A. officinarum rhizomes had anticandidal activity. An explanation could be the 
different methods used in extraction. From the previous report, the hydro-alcoholic 
extract by hot and cold maceration and the methanol extract by percolation did not 
show such antifungal activity. 
 As mentioned earlier that galangin has been proposed to be responsible for 
antibacterial activities of several natural products, it was skeptical whether it was also 
responsible for anticandidal activity found in this study. By disc diffusion method, 
250 g of the extract and 15 g of ketoconazole (positive control) produced 11.0 and 
23.0 mm diameter of clear zone, respectively, whereas 100 g of galangin produced 
only 8.0 mm diameter of clear zone. These results indicated that both galangin and the 
extract possessed antifungal effect against C. albicans, but lower potency than 
ketoconazole.  
 Because galangin was reported to be a major compound in A. officinarum and 
antimicrobial agent, an investigation whether galangin was accountable for 
anticandidal activity was conducted. In this study, the content of galangin in the 
extract was determined. The crude extract of A. officinarum by 80% acetone 
contained relatively low concentration of galangin. After increasing its concentration 
in the sample by TLC, the content of galangin in the extract appear to 3.8 mg/g crude 
extract which is in the range previously reported (2.63-11.6 mg/g) by Tao and 
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coworker (Tao, Wang, Zhu, Lu, and Wei, 2006). Bioautography was conducted to 
investigate whether galangin was the active ingredient. It was found that 10 g of 
galangin which is about 10 times more than the equivalent dose of galangin in the 
extract (0.85 g/250 g) showed no effect on candidal growth. The clear zone on 
bioautography appeared on the spotting position, not galangin. This result indicated 
that galangin was not responsible for antifungal activity of the extract of A. 
officinarum rhizomes found in this study. According to this result, galangin was 
excluded from further experiments. Macro-diffusion method was performed to further 
determine MIC and MFC of the extract. It was found that the extract exhibited 
antifungal activity against C. albicans with MIC and MFC at 1.2 and 2.0 mg/ml 
respectively.  
 Application of SEM analysis of fungal cells has been recommended as useful 
tool for providing lifelike three-dimensional visualization at high resolution. For 
fungi, SEM is commonly used to document morphology and spatial relationships 
(Kaminskyj and Dahms, 2008; Tyagi and Malik, 2010). In this study, SEM analysis of 
the Candida cells revealed changes in morphology after treatment with the crude 
extract. The Candida cells treated with the extract at MIC had coarse surface (Figure 
4.8D), and changed from oval to rounder shape (Figure 4.8F) when treated with MFC. 
These results suggested that the extract possess antifungal activity possibly by 
damaging cell wall, causing C. albicans to form spheroplast and finally death. 
However, this postulated mechanism needs more experiments to confirm the actual 
damage of yeast cell wall.  
 A number of previous studies have shown that Candida biofilms exhibit 
increased resistance to antifungals. Surface roughness has been shown to influence the 
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adhesion of microorganisms to medical devices such as catheters and dental implants 
(Dohnt, Sauer, Müller, Atallah, Weidemann, Gronemeyer, Rasch, Tielen, and Krull 
2011; Douglas, 2002; Estivill, Arias, Torres-Lana, Carrillo-Muñoz, and Arévalo, 
2011; Tarcin, 2011). Although none of many hypotheses has not succeeded to clearly 
explain the phenomenon of increased resistance caused by Candida biofilms, any 
agents which can inhibit its biofilm formation would be clinically useful. An 
inhibitory effect on Candida biofilm formation was investigated using phase contrast 
microscopy and spectrometry. It appeared that both MIC and MFC of the crude 
extract prevented biofilm formation of C. albicans.  
  In conclusion, the result from the present study showed that 80% acetone 
extract of A. officinarum rhizomes or lesser galangal possessed antifungal activity 
against C. albicans with MIC and MFC of 1.2 and 2.0 mg/ml respectively. It also has 
inhibitory effect on biofilm formation. The extract obtained from this study contained 
galangin, which was earlier reported to be a major component, at the amount of 3.8 
mg/g extract. Although galangin exhibited antifungal activity against C. albicans, it 
was not the major active ingredient for this activity because its content in the extract 
is too low. For mechanism underlying the antifungal activity, the results suggested 
that the extract may cause cell wall damage, resulting in cell death. However, this 
postulated mechanism needs more experiments to confirm the actual disruption of 
yeast cell wall. Moreover, the active ingredient(s) responsible for this action need 
further investigation.  
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